CDK2 and breast cancer: Given our observation that CDK4/6-resistant breast cancer cells are markedly sensitive to the addition of INX-315 (IC50 <25 nmol/L), it is plausible that these combinations might be effective using low doses of selective CDK2 inhibitors, thereby improving the overall tolerability profile.